The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

Start Date31 Jan 2026

Sponsor / Collaborator

University of Miami

[+1]

IRCT20190210042676N36

/ RecruitingPhase 2

Evaluation of safety and efficacy profile of the eyelash booster solution containing stemoxydine and bimatoprost on women with hypotrichosis

Start Date21 Dec 2024

Sponsor / Collaborator-

CTIS2023-504759-28-00

/ RecruitingPhase 3

RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES. - BIM-001

Start Date11 Apr 2024

Sponsor / Collaborator

Genetic SpA

100 Clinical Results associated with Bimatoprost

100 Translational Medicine associated with Bimatoprost

100 Patents (Medical) associated with Bimatoprost

1,058

Literatures (Medical) associated with Bimatoprost

01 Nov 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

DoE based development and optimization of ion sensitive in situ nanoemulgel containing bimatoprost for sustained ocular delivery

Article

Author: Singh, Rahul Pratap ; Singh, Monika ; Jhawat, Vikas ; Monika ; Devi, Meena

BACKGROUND:

The primary treatment for glaucoma involves the chronic instillation (daily) of intraocular pressure (IOP)-lowering eye drops to manage disease progression and prevent vision loss. Bimatoprost is a prostaglandin analogue used in glaucoma and ocular hypertension.

OBJECTIVE:

The objective of the present study was to formulate and evaluate a novel in situ nanoemulgel (NEG) of bimatoprost for ocular drug delivery (ODD).

METHODS:

Bimatoprost (Drug), Hyaluronic acid (HA), Algal oil (oil phase), liquid soya lecithin (Emulsifier 1), and tween 40 (emulsifier II), and water (Aqueous phase) were components for the formulation, and the nanoemulsion was prepared by high-pressure homogenization. The optimization of formulation was done with Quality by Design (QbD), and the optimized formulation was further evaluated for Zeta size, Zeta potential, PDI, and Surface morphology. The final nanoemulsion formulation was transformed into a gel system using Gellan Gum (GG) as the gelling agent. After incorporation in the gelling system, the developed nanoemulgel (NEG) was further evaluated for clarity, pH, sol-gel transition, rheology, drug content, sterility, isotonicity, and in vitro drug release. Pharmacodynamic studies have been performed for the evaluation of IOP, Dry eye test, and conjunctival hyperemia measurement.

RESULTS:

Optimized nano emulsion had 7.5 % oil, 22.5 % Liquid soya Lecithin & Tween 40 [S_mix(1:1)] and 70 % water with particle size, Zeta potential and Poly dispersed index (PDI) range as 38.87 ± 0.91, 34.3 ± 0.34 and 0.282 ± 0.04 respectively. The developed formulation (NEG) showed evidence of sol-gel transition or in situ gelation after combining with artificial tear fluid. The drug content in developed NEG was found to be 99.76 ± 0.65 %. In-vitro drug release results of optimized bimatoprost-loaded NEG offered sustained delivery of the drug with an anisotropic diffusion. The developed formulation was found to be stable, isotonic, and sterile. Pharmacodynamic evaluation revealed a significant decrease in IOP with the developed formulation (NEG). Other than this, adverse drug reactions (ADR) associated with anti-glaucoma medication, i.e., dry eye and conjunctival hyperemia, were addressed by developing NEG with omega-3 fatty acid and HA.

CONCLUSION:

This novel formulation offers a competitive option to traditional eye drops because of its prolonged precorneal residence duration and sustained medication release. Pharmacodynamic evaluations demonstrated that the developed NEG formulation enriched with omega-3 fatty acids and hyaluronic acid (HA) provided superior glaucoma management while simultaneously mitigating the adverse effects commonly associated with conventional anti-glaucoma therapies.

24 Sep 2025·Retinal cases & brief reports

Peripapillary retinoschisis associated with open angle glaucoma responding to dorzolamide

Article

Author: Golebka, Jedrzej ; Flynn, Erin ; Chang, Stanley ; Moussa, Omar

Purpose::

Presenting a case of peripapillary retinoschisis in a patient with glaucomatous optic neuropathy that resolved after changing therapy from topical bimatoprost to timolol/dorzolamide.

Methods::

A 70-year-old female who presented for a second opinion for peripapillary retinoschisis in the left eye.

Results::

The patient’s visual acuity was 20/25 and 20/30 in the right and left eyes, respectively. Dilated fundoscopy revealed posterior vitreous detachment (PVD) of the left eye, temporal cupping with a superotemporal notch of the left optic nerve, and bilateral macular drusen and pigmentary changes of the retinal pigment epithelium (RPE). Optical coherence tomography of the macula of the left eye showed a PVD, drusen, and peripapillary retinoschisis extending to and involving the fovea. Topical prostaglandin analogue eye drop was discontinued and replaced by dorzolamide/timolol. The peripapillary retinoschisis resolved after medication change over the following 48 months and has not recurred.

Conclusion::

We present a case of peripapillary retinoschisis in a phakic patient that developed during treatment with a topical prostaglandin analogue. The schisis resolved after switching the prostaglandin analogue to a topical carbonic anhydrase inhibitor. We suggest that the prostaglandin may have had a role in initiating peripapillary retinoschisis associated with glaucomatous optic neuropathy and that carbonic anhydrase inhibitors are a potential treatment for this condition.

01 Sep 2025·EUROPEAN JOURNAL OF OPHTHALMOLOGY

Intraoperative optical coherence tomography in glaucoma surgery with Ex-PRESS ^® implant

Article

Author: Platas Moreno, Irene ; Guerrero Altares, Laura ; Morote, Ignacio Jiménez-Alfaro ; Martin-Gutierrez, M Pilar

Introduction:

To present the correct placement of the Ex-PRESS ® implant in the anterior chamber with the intraoperative optical coherence tomography (i-OCT) scan. To the best of our knowledge, this is the first publication to report the use of i-OCT during an Ex-PRESS ® glaucoma implant procedure.

Case report:

We report the case of a phakic, 48 year-old South American male with bilateral advanced pigmentary glaucoma. Our patient was being treated with dorzolamide-timolol eyedrops twice daily and bimatoprost eyedrops once daily in both eyes. Glaucomatous damage in his left eye had progressed and it was then decided to perform filtering surgery in our patient´s left eye, using a P-50 Ex-PRESS ® shunt and two Ologen ® collagen matrix implants. As our patient was phakic, special care was taken to avoid contact with the lens. The correct placement of both subscleral devices was confirmed with the OPMI LUMERA ® 700 microscope, an i-OCT device. i-OCT scans as well as a video recording were performed throughout the surgical procedure.

Conclusion:

I-Oct can help surgeons to locate the correct placement of implants in cases such as corneal opacification or gerontoxon. This instrument is helpful in the training of ophthalmologists. I-OCT can help surgeons to locate the correct placement of implants in cases with media opacity (such as corneal opacification or gerontoxon) or in phakic patients, where it is important to avoid lens contact. This instrument is helpful in the training of ophthalmologists.

119

News (Medical) associated with Bimatoprost

14 Oct 2025

·www.globenewswire.com

SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001)100% of patients were off all topical IOP-lowering medications at 24 months100% of treated patients achieved 20/30 or better Best Corrected Distance Visual Acuity (BCDVA) at 24 months ALISO VIEJO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced interim 24-month data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System (the BIM-IOL System). The BIM-IOL System, comprising novel, proprietary non-bioerodible drug pads attached to SpyGlass Pharma’s intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The system is designed to consistently deliver multiple years of bimatoprost, a prostaglandin analog approved for the reduction of elevated IOP in patients with OAG or OHT. The interim clinical trial data demonstrated sustained improvements in IOP and visual acuity outcomes, underscoring the potential of the BIM-IOL System to transform care for OAG and OHT patients. “Adherence with daily topical IOP-lowering medications is one of the most consistent challenges for patients in the management of glaucoma and ocular hypertension,” said Malik Kahook, M.D., Co-founder of SpyGlass Pharma. “The findings at 24 months demonstrated that patients can achieve meaningful and durable reduction in IOP without the burden of daily drops. We are pleased to share these interim results and continue our objective of delivering a long-term, drop-free solution for patients in need.” The single-center, prospective first-in-human trial is designed to evaluate the BIM-IOL System for the treatment of elevated IOP in patients with OAG or OHT undergoing routine cataract surgery. At 24 months, the BIM-IOL System demonstrated: 42% reduction in mean IOP, from 25.1 ± 2.5 mmHg at baseline post-washout to 14.5 ± 3.0 mmHg (p<0.0001), with no statistically significant difference in IOP reduction across the three dosage groups tested.100% of patients were off all topical IOP-lowering medications.Best corrected distance visual acuity (BCDVA) improved to 20/30 or better in all patients. Overall, the BIM-IOL System was observed to be well-tolerated. All observed adverse events were considered to be related to the cataract procedure and none were deemed to be associated with the BIM-IOL System. No serious adverse events were observed. “The 24-month findings from our first-in-human trial add to our growing body of data supporting the long-term durability of the BIM-IOL System,” added Patrick Mooney, Chief Executive Officer of SpyGlass Pharma. “With an implantation technique familiar to all cataract surgeons, including the two-thirds of physicians who do not routinely perform minimally invasive glaucoma surgery, we believe our system has the potential to become a widely-implemented solution for reducing reliance on topical medication." ABOUT THE BIM-IOL SYSTEM SpyGlass Pharma’s lead product candidate, the BIM-IOL System, comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). The BIM-IOL System is designed to consistently deliver multiple years of bimatoprost, a prostaglandin analog approved for topical use by the U.S. Food and Drug Administration (FDA) in 2001, for the reduction of elevated IOP in patients with OAG or OHT. The company is planning initiation of two registrational Phase III clinical trials of the BIM-IOL System by end of year and continues long-term follow-up of patients in its first-in-human trial. SpyGlass Pharma completed enrollment in a Phase I/II study to investigate the safety and efficacy of the BIM-IOL System in a larger patient pool. SpyGlass Pharma plans to work with the FDA to advance the program through Phase III clinical trials, New Drug Application (NDA) submission, and ultimately to potential commercial approval. ABOUT SPYGLASS PHARMA SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company’s mission is to redefine the management of these conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. The SpyGlass Platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Platform was originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine. For more information, visit: www.spyglasspharma.com. Media Contact:Nami Surendranath+1 (212) 418-8981nsurendranath@dnacommunications.com Investor Contact:Ami Bavishi or Nick ColangeloGilmartin Group LLCinvestors@spyglasspharma.com

Clinical ResultPhase 3

14 Oct 2025

·www.globenewswire.com

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations

Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 months Other analyses broadly in line with the trends seen for Mont Blanc Data presentations planned for upcoming ophthalmology conferences October 2, 2025 – Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has completed the additional pre-planned analyses of the NCX 470 Denali Phase 3 clinical trial data. These analyses confirm an efficacy profile similar to that seen in subgroup analysis of the Mont Blanc trial. In addition, reduction in intraocular pressure (IOP) was measured in the long-term safety extension period of the Denali trial from 6 months through to 12 months. NCX 470 maintained robust IOP reduction during this period with no additional safety signals seen. New Drug Applications (NDAs) for NCX 470 are in preparation for the U.S. and China. A full summary of the status of NCX 470 was given in our Press Release of September 4, 2025. The Company plans to publish further data at upcoming ophthalmology conferences. NCX 470 NDA submission in the United States: expected in H1 2026. NCX 470 NDA submission in China: expected shortly after submission in the U.S. NCX 470 Phase 3 clinical program in Japan: Program initiated in summer 2025. Managed and financed by Kowa. Similar to Mont Blanc, Denali is a randomized, multi-regional, double-masked, parallel group trial that evaluated the safety and efficacy of NCX 470 ophthalmic solution, 0.1% compared to latanoprost ophthalmic solution, 0.005% in 696 patients in 90 sites in the U.S. and China. Latanoprost is the most widely prescribed first-line therapy for open-angle glaucoma or ocular hypertension. The primary efficacy evaluation was based on reduction from baseline in mean time-matched IOP at 6 timepoints: 8 AM and 4 PM at week 2, week 6 and month 3. The Denali trial also included a long-term safety extension from 6 months through to 12 months and was jointly conducted and equally financed with our Chinese partner, Ocumension Therapeutics. Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). The content above comes from the network. if any infringement, please contact us to modify.

Clinical Study

23 Sep 2025

·www.globenewswire.com

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segmentBRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN® (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company. Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. “We are pleased to add another key ophthalmic therapy to our Affordable Medicines portfolio,” said Dr. Srinivas Kone, Senior Vice President, Chief Scientific Officer – Affordable Medicines. “As the prevalence of glaucoma continues to rise, particularly among the aging population, it is critical that patients and providers have affordable access to effective treatments such as bimatoprost. This represents our most recent complex new product approval this year and an important growth driver for our Affordable Medicines segment.” The most common adverse reaction associated with bimatoprost ophthalmic solution 0.01% is conjunctival hyperemia. For prescribing information, see package insert here. According to IQVIA® U.S. annual sales for bimatoprost ophthalmic solution 0.01% for the 12 months ended July 2025 were approximately $685 million. Note: LUMIGAN® is a registered trademark of Allergan, Inc., an AbbVie company. About AmnealAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn. Cautionary Statement on Forward-Looking StatementsCertain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. Investor Contact Anthony DiMeoVP, Investor Relations anthony.dimeo@amneal.com Media ContactBrandon SkopSr. Director, Corporate Communicationsbrandon.skop@amneal.com

Drug Approval

100 Deals associated with Bimatoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D02724	Bimatoprost	S01EE03	DB00905

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Takeda Pharmaceutical Co., Ltd.	07 Jul 2009
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	07 Jul 2009
Hypotrichosis	United States	AbbVie, Inc.	24 Dec 2008
Glaucoma, Open-Angle	United States	AbbVie, Inc.	16 Mar 2001
Ocular Hypertension	United States	AbbVie, Inc.	16 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hydrophthalmos	Phase 3	United States	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	France	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Italy	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Philippines	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Taiwan Province	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	United Kingdom	Allergan UC	01 Sep 2011
Alopecia	Phase 3	Japan	Allergan UC	01 Jul 2011
Cataract	Phase 2	United States	SpyGlass Pharma Inc	13 Oct 2023
Androgenetic Alopecia	Phase 2	United States	Allergan UC	01 Jun 2011
Androgenetic Alopecia	Phase 2	Germany	Allergan UC	01 Jun 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


FDA_CDER Manual	Not Applicable	Glaucoma, Open-Angle \| Ocular Hypertension	-	0.01% ZOLYMBUS	ldlozsejxe(oegwccuqiw) = OLYMBUS once daily (in the evening) was non-inferior to preserved bimatoprost ophthalmic solution 0.01%. tqmurfqzig (nmoatxlfgk ) View more	Positive	09 Sep 2025
				0.01% preserved bimatoprost ophthalmic solution
NCT03850782 (TRITON, Pubmed \| Drugs)	Phase 3	Ocular Hypotension	441	Bimatoprost implant 10 µg	fjyudpcskp(jdqnxtofml) = qgphgdypqi qyziaotzfb (pnkrvnbcyg, 369 - 485) View more	Positive	22 Feb 2025
NCT04747808 (BusinessWire) Manual	Phase 2	Glaucoma	-	LL-BMT1LL-BMT1 32-µg dose	matbxmdlsj(txjvdbnwdl) = eusjllloaz yeekoydyat (wrzlbzyask ) View more	Positive	12 Nov 2024
				bimatoprostbimatoprost 0.01%	-
NCT02507687 (CTgov)	Phase 3	Glaucoma, Open-Angle	240	SLT (Stage 2: SLT)	zdlwntdxvh(xlfaeumqwl) = kmlqpbcukh hkbmqiyyeb (pxservghvq, 0.28) View more	-	10 May 2024
				Bimatoprost SR (Stage 2: Bimatoprost SR 10 µg)	zdlwntdxvh(xlfaeumqwl) = htuqhvtyoe hkbmqiyyeb (pxservghvq, 0.28) View more
NCT03825380 (CTgov)	Phase 3	Glaucoma, Open-Angle \| Glaucoma	485	Bimatoprost (T4032)	boorrskbli(ezvfzleevq) = hogffpvlaz gqhypjxsnc (vqrmcubrgv, 0.19) View more	-	21 Nov 2023
				Lumigan® (Lumigan®)	boorrskbli(ezvfzleevq) = nytrhmqfnh gqhypjxsnc (vqrmcubrgv, 0.18) View more
NCT04285580 (CTgov)	Phase 3	Glaucoma, Open-Angle	37	Bimatoprost SR (Bimatoprost SR 10 μg)	qrakisztsf(ndcaxjojym) = dcbqzlhyxz txibqxawvd (jmxlazqaiv, 5.65) View more	-	08 Jun 2023
				LUMIGAN (LUMIGAN 0.01%)	qrakisztsf(ndcaxjojym) = klflosbtke txibqxawvd (jmxlazqaiv, 5.27) View more
NCT02250651 \| NCT01157364 \| NCT02247804 (Pubmed)	Phase 3	Ocular Hypertension \| Glaucoma, Open-Angle	-	Bimatoprost implant 10 µg	ztuopxihxt(vklydtdsur) = iyhuanpewh vcxkxsurbd (txbdicmjfo )	-	28 May 2022
				Topical timolol maleate 0.5%	ztuopxihxt(vklydtdsur) = gmnvwtgayy vcxkxsurbd (txbdicmjfo )
NCT03850782 (Phase 3b Study, ARVO2022)	Phase 3	Ocular Hypotension	203	Bimatoprost implant	hjvcgdxzhd(cwsasgwboy) = nhuubbleuf wzdmenlxwl (isvfufpupn )	-	01 May 2022
ARVO2022	Not Applicable	Glaucoma	122	Bimatoprost SR implantation	skrfzbqhqc(gyvzrerbho) = gbzkhwqlfd slkusbgalb (eejqqdobhs )	-	01 May 2022
NCT03891446 (PO080, AAO2021)	Phase 3	Glaucoma, Open-Angle	200	Bimatoprost implant 10μg	kftxxrnchp(mppvngwaiy) = cqaeubmkdl fqsbgpsjmt (gbeaxjxcdg, 3.6)	Positive	13 Nov 2021
				Bimatoprost implant 15μg	kftxxrnchp(mppvngwaiy) = xnnjtinaoe fqsbgpsjmt (gbeaxjxcdg, 3.2)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bimatoprost

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation